<DOC>
	<DOCNO>NCT00110032</DOCNO>
	<brief_summary>This phase I trial study side effect fluorine F18 EF5 give positron emission tomography find oxygen tumor cell patient undergo surgery biopsy newly diagnose brain tumor . Diagnostic procedure use fluorine F 18 EF5 positron emission tomography detect tumor hypoxia may help plan cancer treatment</brief_summary>
	<brief_title>Positron Emission Tomography Using Fluorine F 18 EF5 Find Oxygen Tumor Cells Patients Who Are Undergoing Surgery Biopsy Newly Diagnosed Brain Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety fluorine F 18 EF5 ( ^18F-EF5 ) patient newly diagnose brain tumor undergo surgery biopsy . Secondary I . Determine pharmacokinetics biodistribution ^18F-EF5 administer nonradioactive EF5 patient . II . Determine ability positron emission tomography ( PET ) scan use ^18F-EF5 detect tumor hypoxia patient . III . Determine presence pattern nonradioactive EF5 binding immunohistochemistry ( IHC ) and/or flow cytometry patient . IV . Correlate tumor hypoxia , measure PET scan use ^18F-EF5 , EF5 stain IHC and/or flow cytometry recurrence-free survival patient . OUTLINE : Patients assign 1 3 group . Group 1 : Patients receive fluorine F 18 EF5 ( ^18F-EF5 ) IV follow whole brain whole body positron emission tomography ( PET ) scanning OR whole body PET scanning . Patients receive nonradioactive EF5 IV 1-2 ½ hour . Group 2 : Patients receive nonradioactive EF5 IV 1-2½ hour follow ^18F-EF5 IV . Patients undergo whole brain whole body PET scan . Group 3 : Patients receive nonradioactive EF5 ^18F-EF5 group 2 . Patients undergo whole brain PET scanning . Approximately one day EF5 administration , patient undergo surgery biopsy tumor AND biopsy normal skin adjacent incision . Patients follow 2-4 week 4-6 week EF5 administration every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually thereafter .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Craniopharyngioma</mesh_term>
	<mesh_term>Adamantinoma</mesh_term>
	<mesh_term>Choroid Plexus Neoplasms</mesh_term>
	<mesh_term>Pinealoma</mesh_term>
	<mesh_term>Hemangiopericytoma</mesh_term>
	<mesh_term>Glioma , Subependymal</mesh_term>
	<mesh_term>Etanidazole</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<criteria>Histologically confirm and/or clinical image evidence de novo mass likely brain tumor Amenable debulking surgery surgical resection biopsy standard initial therapy tumor Performance status Karnofsky 70100 % At least 3 month WBC count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin &lt; 1.2 mg/dL Creatinine &lt; 1.3 mg/dL No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No significant cardiac condition would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study participation Weight ≤ 130 kg No peripheral neuropathy ≥ grade 3 No history allergic reaction attribute metronidazole No uncontrolled illness No psychiatric illness social situation would preclude study compliance No medical condition would preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>